Bradley W. Popovich

Learn More
Group recommended a panel of mutations and variants that should be tested to determine carrier status within the CFTR gene as a part of population screening programs. 1,2 This was initially done in response to the recommendations of an NIH CF Consensus Conference that CF carrier screening be considered by all couples for use before conception or prenatally.(More)
Precision or personalized medicine through clinical genome and exome sequencing has been described by some as a revolution that could transform healthcare delivery, yet it is currently used in only a small fraction of patients, principally for the diagnosis of suspected Mendelian conditions and for targeting cancer treatments. Given the burden of illness in(More)
  • 1